Page last updated: 2024-09-05

n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid and Mesothelioma

n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid has been researched along with Mesothelioma in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baidoo, KE; Brechbiel, MW; Garmestani, K; Milenic, DE; Nayak, TK1

Other Studies

1 other study(ies) available for n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid and Mesothelioma

ArticleYear
HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts.
    PloS one, 2011, Mar-25, Volume: 6, Issue:3

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody Specificity; Cetuximab; ErbB Receptors; Flow Cytometry; Humans; Isothiocyanates; Mesothelioma; Mice; Molecular Targeted Therapy; Panitumumab; Pentetic Acid; Positron-Emission Tomography; Time Factors; Tissue Distribution; Xenograft Model Antitumor Assays; Yttrium Radioisotopes

2011